• NEO

Earnings call: NeoGenomics sees growth with NGS and new test launches

NeoGenomics reported Q3 2024 results with a 10% revenue increase to $168M, driven by clinical services and NGS growth, highlighting financial strength and strategic initiatives for future growth.